1.Zhang, Z., et al., Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther, 2020. 5(1): p. 113.
2.Nosengo, N., Can you teach old drugs new tricks? Nature, 2016. 534(7607): p. 314-6.
3. Frantzi, M., et al., Drug repurposing in oncology. Lancet Oncol, 2020. 21(12): p. e543.
4.Kaiser, J., An old drug for alcoholism finds new life as cancer treatment. Science News, 2017.
5.Skrott, Z., et al., Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature, 2017. 552(7684): p. 194-199.
6.Nechushtan, H., et al., A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer. Oncologist, 2015. 20(4): p. 366-7.
7.Huang, J., et al., A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. J Neurooncol, 2019. 142(3): p. 537-544.
8.Halama, N., et al., Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. Cancer Cell, 2016. 29(4): p. 587-601.
9.Kulkarni, A.S., S. Gubbi, and N. Barzilai, Benefits of Metformin in Attenuating the Hallmarks of Aging. Cell Metab, 2020. 32(1): p. 15-30.
10.Bailey, C.J., Metformin: historical overview. Diabetologia, 2017. 60(9): p. 1566-1576.
11.Emil Alphonse Werne, J.B., The preparation of methylguanidine, and of ββ-dimethylguanidine by the interaction of dicyanodiamide, and methylammonium and dimethylammonium chlorides respectively. JChemSocTrans, 1922. 121: p. 1790-1794.
12.Mc, K.J., K. Kuwayti, and P.P. Rado, Clinical experience with DBI (phenformin) in the management of diabetes. Can Med Assoc J, 1959. 80(10): p. 773-8.
13.Saraei, P., et al., The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manag Res, 2019. 11: p. 3295-3313.
14.Noto, H., et al., Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One, 2012. 7(3): p. e33411.
15.Margel, D., et al., Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol, 2013. 31(25): p. 3069-75.
16.Arrieta, O., et al., Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol, 2019. 5(11): p. e192553.
17.Sonnenblick, A., et al., Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. J Clin Oncol, 2017. 35(13): p. 1421-1429.
18.Higurashi, T., et al., Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol, 2016. 17(4): p. 475-483.
19.Kordes, S., et al., Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol, 2015. 16(7): p. 839-47.
20.Li, L., et al., Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial. Clin Cancer Res, 2019. 25(23): p. 6967-6975.
21.Hu, J., et al., Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A, 2009. 106(9): p. 3342-7.
22.Zhang, X.W., et al., Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science, 2010. 328(5975): p. 240-3.
23.Ingalls, T.H., F.J. Curley, and P. Zappasodi, Thalidomide Embryopathy in Hybrid Rabbits. N Engl J Med, 1964. 271: p. 441-4.
24.Stolberg, S.G., Their Devil's Advocates. The New York Times, 1998.
25.Singhal, S., et al., Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 1999. 341(21): p. 1565-7.